Algernon Logo 1.png
Algernon Announces Warrant Extension
04. November 2024 18:30 ET | Algernon Pharmaceuticals Inc.
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces Closing of Private Placement
20. August 2024 07:00 ET | Algernon Pharmaceuticals Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN)...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces Increase to Private Placement
13. August 2024 07:18 ET | Algernon Pharmaceuticals Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN)...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces Private Placement
07. August 2024 17:02 ET | Algernon Pharmaceuticals Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN)...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces Closing of Private Placement
02. August 2024 07:00 ET | Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces Increase to Private Placement
31. Juli 2024 07:00 ET | Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, July 31, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage...
Algernon Logo 1.png
Algernon Pharmaceuticals Reports Results of Study Showing 93% Cough Suppression with Ifenprodil
16. Juli 2024 08:00 ET | Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces Private Placement
11. Juli 2024 16:15 ET | Algernon Pharmaceuticals Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN)...
Algernon Logo 1.png
Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services
21. Mai 2024 07:00 ET | Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 21, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
Algernon Logo 1.png
Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024
11. April 2024 07:00 ET | Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to invite...